Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: A case-control study of Asian patients

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 6, 2011, Pages 521-527

  Song, Myeong Jun ^a   Park, Chung Hwa ^a   Kim, Jin Dong ^a   Kim, Hee Yeon ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a   Chun, Ho Jong ^b   Choi, Byung Gil ^b   Lee, Hae Giu ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Chemoembolization; drug eluting bead; hepatocellular carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; ASIAN; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG RELEASE; DRUG SAFETY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; DOXORUBICIN; DRUG CARRIERS; ETHIODIZED OIL; FEMALE; HEPATIC ARTERY; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; REPUBLIC OF KOREA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 79955592371     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328346d505     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108 (Pubitemid 40372904)
2. Olsen AH, Parkin DM, Sasieni P. Cancer mortality in the United Kingdom: Projections to the year 2025. Br J Cancer 2008; 99:1549-1554
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of the hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521
4. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost-effectiveness analysis. Gut 2001; 48:251-259 (Pubitemid 32141852)
5. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126:1005-1014 (Pubitemid 38451172)
6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 (Pubitemid 43112690)
7. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89:500-507 (Pubitemid 30640096)
8. Cucchetti A, Piscaglia F, Caturelli E, Benvegn L, Vivarelli M, Ercolani G, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16:413-422
9. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al.; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711
10. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52:762-773
11. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429-442 (Pubitemid 36152543)
12. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474-481 (Pubitemid 46201723)
13. Poon RT, Tso WK, Pang RW, Ng KK,Woo R, Tai KS, Fan ST. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intraarterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5:1100-1108
14. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomised study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52
15. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Beadblock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:541-551
16. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21:327-332
17. Llovet JM, Br̊ C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19:329-338
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60
19. Song IH, Kim KS. Current status of liver diseases in Korea: Hepatocellular carcinoma. Korean J Hepatol 2009; 15 (Suppl 6):S50-S59
20. Yun EH, Lim MK, Oh JK, Park JH, Shin A, Sung J, Park EC. Combined effect of socioeconomic status, viral hepatitis, and lifestyles on hepatocelluar carcinoma risk in Korea. Br J Cancer 2010; 103:741-746.